Writing Group Disclosures
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Tiffany M. Powell-Wiley | National Institutes of Health | NIH (funded intramural investigator at NIH)† | None | None | None | None | None | None |
| Paul Poirier | Universite Laval, Faculte de Pharmacie Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Canada) | None | None | Abbott*; Amgen*; Astra-Zeneca*; Bausch Health*; Bayer*; Boehringer Ingelheim*; Eli Lilly*; Janssen*; Novartis*; Novo Nordisk*; Sanofi*; Servier*; HLS Therapeutics* | None | None | Amgen*; Bausch Health*; Bayer*; Boehringer Ingelheim*; Eli Lilly*; Janssen*; Novartis*; Novo Nordisk*; Servier*; Sanofi* | None |
| Lora E. Burke | University of Pittsburgh | NIH† | None | None | None | None | None | NIH (principal investigator)† |
| Jean-Pierre Després | Université Laval, VITAM – Centre de recherche en santé durable (Canada) | Fondation IUCPQ-UL (coinvestigator)†; CIHR (PI)† | None | None | None | None | None | None |
| Penny Gordon-Larsen | Gillings School of Global Public Health, University of North Carolina at Chapel Hill | NIH (principal investigator)*; NIH (coinvestigator)* | None | None | None | Astra Zeneca (immediate family members)*; Amgen (immediate family members)*; Johnson & Johnson (immediate family members)*; Pfizer (immediate family members)*; Merck (immediate family members)* | NIDDK*; Boston Nutrition Obesity Research Center* | None |
| Carl J. Lavie | Ochsner Medical Center | None | None | AstraZeneca/FARXIGA* | None | None | AstraZeneca/FARXIGA* | None |
| Scott A. Lear | Simon Fraser University, St. Paul’s Hospital (Canada) | Robert Wood Johnson Foundation†; Hamilton Health Sciences (research contract)† | None | None | None | None | None | None |
| Chiadi E. Ndumele | Johns Hopkins University | NIH (grant on mechanisms linking obesity to heart failure)† | None | None | None | None | None | None |
| Ian J. Neeland | University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine | NIH/NIDDK (K23 career development grant)† | None | None | None | None | Merck* | None |
| Prashanthan Sanders | University of Adelaide and Royal Adelaide Hospital (Australia) | None | None | None | None | None | None | None |
| Marie-Pierre St-Onge | Columbia University, Irving Medical Center | None | None | None | None | None | None | None |
| Leena P. Bharath | Merrimack College | None | None | None | None | None | None | None |
| Kevin P. Davy | Virginia Polytechnic Institute and State University | None | None | None | None | None | None | None |
| Francisco Lopez-Jimenez | Mayo Clinic | None | None | None | None | None | None | None |
| Eric D. Peterson | Duke Clinical Research Institute | Novo Nordisk*; AstraZeneca†; Janssen† | None | None | None | None | AstraZeneca*; Janssen* | None |
| Stephen Sidney | Kaiser Permanente | NHLBI (1RC2HL101666, relating to surveillance of cardiovascular disease, including stroke, in the Cardiovascular Research Network)†; NINDS (1U54NS081760-01, Stroke Prevention/Intervention Program [SPIRP])† | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.